Format

Send to

Choose Destination
Nat Commun. 2011;2:308. doi: 10.1038/ncomms1306.

Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.

Author information

1
Department of Pediatrics, Kobe University Graduate School of Medicine, Chuo, 7-5-1 Kusunoki-cho, Kobe 650-0017, Japan.

Abstract

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease caused by a loss of the dystrophin protein. Control of dystrophin mRNA splicing to convert severe DMD to a milder phenotype is attracting much attention. Here we report a dystrophinopathy patient who has a point mutation in exon 31 of the dystrophin gene. Although the mutation generates a stop codon, a small amount of internally deleted, but functional, dystrophin protein is produced in the patient cells. An analysis of the mRNA reveals that the mutation promotes exon skipping and restores the open reading frame of dystrophin. Presumably, the mutation disrupts an exonic splicing enhancer and creates an exonic splicing silencer. Therefore, we searched for small chemicals that enhance exon skipping, and found that TG003 promotes the skipping of exon 31 in the endogenous dystrophin gene in a dose-dependent manner and increases the production of the dystrophin protein in the patient's cells.

PMID:
21556062
PMCID:
PMC3113229
DOI:
10.1038/ncomms1306
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center